Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma
Stock Information for Citius Pharmaceuticals Inc.
Loading
Please wait while we load your information from QuoteMedia.